Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Ovarian Cancer treatment details. Biologic therapy. Chemotherapy. University MedicalCenter Utrecht Cancer Center, Utrecht, Netherlands



Survival: 13.1 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: Netherlands
   
City/State/Province: Utrecht
   
Hospital: University MedicalCenter Utrecht Cancer Center
   
Journal: Link
   
Date: 11/2010

Description:
Patients:
This study involved 26 women with platinum-resistant ovarian cancer. The median age was 60 years.

Treatment:
Patients were treated with the chemotherapy agent pegylated liposomal doxorubicin and the biologic therapy agent atrasentan, which inhibits a protein called ETaR that is involved in cancer cell growth.

Toxicities:
The maximum toxicity level reported was of grade 4 and included nausea/vomiting, mucositis (inflammation of the lining of the GI tract), and headache.

Results:
The median overall survival in this study was 13.1 months.

Support:
This study was supported by Abbot Laboratories, the makers of atrasentan (brand name: Xinlay).

Correspondence: Dr. Petronella O. Witteveen; email: P.O.Witteveen@umcutrecht.nl

E-mail to a Friend Email Physician More Information